Key result
High COMPASS-31 score linked to ~4.3-fold higher cardiovascular hospitalization risk in ATTR cardiomyopathy.
Why the study?
ATTR is a systemic disease affecting both the heart and nervous system, and the distribution of autonomic symptoms across ATTR-CM subtypes and the prognostic impact of autonomic dysfunction required evaluation.
Does severe autonomic dysfunction as measured by a high COMPASS-31 score (>=35.42) predict adverse cardiovascular outcomes, specifically cardiovascular hospitalizations, in patients with ATTR cardiomyopathy?
Cohort (n=240)
No
Does severe autonomic dysfunction as measured by a high COMPASS-31 score (>=35.42) predict adverse cardiovascular outcomes, specifically cardiovascular hospitalizations, in patients with ATTR cardiomyopathy?
Autonomic dysfunction assessed via the COMPASS-31 questionnaire (score >=35.42) is associated with worse quality of life, more advanced disease stage, and a >4-fold independent increase in cardiovascular hospitalization risk among patients with ATTR cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Patient-reported outcome measures (PROMs) are increasingly used to monitor patients with ATTRwt, assess individual trajectories, and determine disease progression. Such information allows closer monitoring of their risk of functional decline, frailty, recurrent falls, repeated hospitalizations, increased mortality, and high caregiver burden.”
High COMPASS-31 scores may flag ATTR cardiomyopathy patients needing closer monitoring; leaves open whether autonomic screening improves risk stratification or outcomes.
Background ATTR is a systemic disease, causing significant morbidity and mortality, manifesting with symptoms affecting both the heart and nervous system. This study employed the Composite Autonomic Symptom Scale 31 (COMPASS-31) to assess autonomic symptoms in relation to ATTR-CM subtypes and the impact of dysfunction on prognosis.Methods This study included contemporary ATTR-CM patients enrolled in an institutional registry from 7/21-6/24. Demographic information, patient-reported outcomes (COMPASS-31 and Kansas City Cardiomyopathy Questionnaire (KCCQ)), 6-min walk test, and clinical data (hospitalisations, mortality) were collected and compared between ATTR-CM sub-types (ATTRwt, ATTRv-Val122Ile, ATTRv-non Val122Ile).Results 240 ATTR-CM patients (81% ATTRwt, 11% Val-122Ile, 8% non-Val122Ile) were studied. Following adjustment for age, significant COMPASS-31 score differences were observed between ATTRwt and ATTRv-nonV122I variant patients. “High” COMPASS-31 scores (≥35.42) were associated with later Columbia stage, lower exercise tolerance, and poorer quality of life (QOL) (all p < 0.05). Time-to-event analysis demonstrated higher probability of cardiovascular hospitalisations (CVH) for patients with “High” COMPASS-31 scores (p < 0.01). These patients also had increased CVH risk (HR = 4.26 [95% CI: 1.85–9.83], p = 0.001) independent of age, sex, ATTR type, Columbia Stage and diabetes.Conclusions Among ATTR-CM patients, autonomic dysfunction assessed via COMPASS-31 questionnaire was associated with more advanced disease stage and QOL impairment, and independently predicted CVH risk.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Weinsaft et al. (2025) conducted a cohort in Transthyretin amyloid cardiomyopathy (ATTR-CM) (n=240). High COMPASS-31 score (>=35.42) indicating autonomic dysfunction vs. Low COMPASS-31 score (<35.42) was evaluated on Cardiovascular hospitalization (CVH) (HR 4.26, 95% CI 1.85-9.83, p=0.001). High COMPASS-31 scores independently predicted an increased risk of cardiovascular hospitalization in patients with ATTR cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: